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Abstract 
Contemporary therapies to rationalize the hyperglycaemia in type 2 diabetes mellitus (T2DM) 
generally involve insulin-dependent mechanisms and lose their effectiveness as pancreatic b-cell 
function decreases to a greater extent. Kidney emerges out as a novel and potential target to trim 
down the T2DM. The filtered glucose is reabsorbed principally through the sodium glucose co-
transporter-2 (SGLT2), a low affinity transport system, which are present at the luminal surface 
cells that covers the first segment of proximal tubules. Competitive inhibition of SGLT2 
therefore represents an innovative therapeutic strategy for the treatment of hyperglycaemia 
and/or obesity in patients with type 1 or type 2 diabetes by enhancing glucose and energy loss 
through the urine. Selective inhibitors of SGLT2 reduce glucose reabsorption, causing excess 
glucose to be eliminated in the urine; this decreases plasma glucose. SGLT2 inhibitors are 
coupled with osmotic dieresis and loss of weight which aid in reducing the blood pressure. The 
observation that individuals with familial renal glycosuria maintain normal long-term kidney 
function provides some encouragement that this mode of action will not adversely affect renal 
function. This novel mechanism of targeting kidney for the treatment of T2DM is reasonably 
valuable and is independent of insulin and clutch with the low risk of hypoglycemia.  
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Introduction: 
Diabetes has become an engorgement apprehension worldwide. More or less 285 million people 
all over the world will be suffering from diabetes by the end of 2010. WHO estimates that more 
than 346 million people worldwide have diabetes [1]. This number is likely to more than double 
by 2030 without intervention. Almost 80% of diabetes deaths occur in low- and middle-income 
countries. The most common disorder of glucose homeostasis is type2 diabetes mellitus (T2DM). 
It accounts for 90-96% of all cases of diabetes [2]. Sodium-dependent glucose cotransporters 
(SGLTs) facilitate the transport of glucose against a concentration gradient with synchronized 
transport of sodium down a concentration gradient [3]. The anticipation is there is about 90% of 
total renal glucose reabsorption is aided by SGLT2. Thus a new therapeutic approach without 
dependence on insulin and appropriate for use in amalgamation with other agents would be 
preeminent choice for treatment of hyperglycemia in type 2 diabetes mellitus (T2DM). Sodium 
Glucose co-transporter inhibitors create a center of attention as there is a need of potential 
therapy for diabetes mellitus with lesser side effects.[5]. This review scrutinize the niceties of 
various SGLT2 inhibitors  
 
The role of SGLT is fundamental in the mutual transfer of sugar and sodium across the epithelial 
membrane. The transport of sugar takes place in the small intestine and the renal tubule through 
active transport. It necessitates the coupling of cellular energy metabolism to the transepithelial 
transfer. It is SGLT where the coupling takes place.  There is no hydrolysis of ATP is engaged as 
compared to the primary active transport episodes for instance those intervened by ion 
translocating ATPases. As an alternative the SGLT exploit the energy accumulated in an ion 
gradient for the translocation of sugars against the concentration gradient. Sodium is the major 
ion present in the mammals whose gradient across the cell membrane has been used as thrust. 
The secondary active transport of sugars, carboxylic acid and the aminoacids rivet the 
synchronized movement of sodium ions by and large in the same direction as the substrate. [6] 
(Kinne 1991). (Figure No.1) 
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Kidney is the main organ where active transport of sugar takes place in the early part of the 
proximal tubule.  Research work on the transport of sugar in the early and late segments of 
proximal tubule and vesicles demonstrate that the kidney contains two D-glucose cotransporters 
with the difference in their stoichiometry for sodium in the early proximal tubule. There is a 
mutual translocation of one sugar and one sodium molecule in the luminal membrane while two 
sodium ions are transferred with one sugar molecule in the late part of proximal tubule. There is 
a divergence in the affinity for D-glucose for the two transporters. [7] (Burckhardt and Kinne 
1992). (Figure No.2) 
The transporter in the early part has been identified as SGLT1 at the same time the transporter 
found in the early proximal tubule as SGLT2. 
 
The sodium gluocose cotransporter (SGLT2) is a high capacity, low affinity proximal tubular 
cell transporter that reabsorbs filtered glucose. Mutations in this transporter lead to renal 
glycosuria. In diabeteic animal models, there appears to be upregulation of the SGLT2 receptors 
and GLUT2mRNA. SGLT2 antagonism provides an interesting therapeutic option to decrease 
glucose loads in diabetes. Nonspecific SGLT2 inhibitors like phlorizin have disturbing 
gastrointestinal side effects. More specific inhibitors like dapagliflozin and sergiflozin are being 
tested in small clinical trials. The effect on the progression of diabetic kidney disease remains to 
be studied. [8] (Wright et al. 2007)  
 
Sodium-D-Gluocse transportation: Molecular Aspect 
Discovery of human intestinal SGLT1 by Ernie Wright and his acquaintances pave the way for 
the identification of an identical gene in the kidney [9] (Morrison et al. 1991). This further 
allowed the researchers to do mutagenesis studies, structural elucidation and the discovery of 
substrate binding sites as well as inhibitor binding sites [8] (Wright et al. 2007). 
The extensive research on the membrane topology of the transporter which was possible only 
after the acquaintance of the sequence was done. The research showed that the N-terminus of 
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thee transporter is pointing outside of the cell with 14 transmembrane segments. The position of 
the loop 13-14 is essential after pholrizin binding site requires the loop 13-14. The C-terminus 
also plays a vital role in the recognition and translocation of the sugar. [8] (Wright et al. 2007). 
The N-terminal segments IV-V are implicated in the recognition of sodium as well as glucose 
binding. (Table No.1) 
 
SGLT: Binding situate 
After exhaustive research it has been established that sugars in the hexose and D-configuration 
are transferred while sugars with L-configuration are unable to be transferred. The hydroxyl 
group at C2 position must be present in the equilateral manner in order to transport the sugars. 
Consequently the presence of hydroxyl group at C3 position is also plays a vital role. The 
hydroxyl group at C6 is of not much importance. SGLT2 have one hydrophobic binding site at 
C6 position therefore the alkyl residues present at C6 have higher affinity than SGLT1. [10] 
(Kipp et al. 1997). 
Table No. 1: Pharmacodynamic parameters of SGLT2 inhibitors currently in development 
Compound Selectivity for 
SGLT2 vs. SGLT1 
(Fold) 
UGE in humans at 
highest dose; mean 
value ±SDa (g/day) 
Reduction in HbA1c 
(%) 
ASP1941 255 (ref. 28) 90.8 ± 16.0 (ref. 29) 
58.9 ± 14.6 (ref. 31) 
50 (ref. 30) 
−0.8 (ref. 30) 
BI 10773 >2,500 (ref. 32) 72.6 ± 35.9 (ref. 33) 
88 ± 20.3 (ref. 34) 
90.8 (ref. 35) 
NR 
Canagliflozin 414 (ref. 36) 129.2 ± 20.8 SE (ref. 
37) 
113 (ref. 38) 
−0.92 (ref. 37) 
Dapagliflozin 1,200 (ref. 39) 70 (ref. 22) −0.61 to −0.89 
(refs. 16–19) 
LX4211 20 (ref. 40) 80 (ref. 40) −1.25 (ref. 40) 
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aSD unless otherwise indicated; SD/SE was not reported in some studies. 
HbA1c, hemoglobin A1c; NR, not reported; SD, standard deviation; SE, standard error; 
UGE, urinary glucose excretion. (Copyright 2011, American Society for Clinical Pharmacology and Therapeutics, 
Adapted with permission from M Pfister et al, Inhibition of SGLT2: A Novel Strategy for Treatment of Type 2 
Diabetes Mellitus, Clinical Pharmacology & Therapeutics, vol 89, No. 4, April 2011.) 
 
Novel SGLT2 inhibitors: 
1. Phlorizin:  
It is beta glucoside obtained from the bark of apple roots. Phlorizin normalized plasma 
glucose and corrected glucotoxicity induced decline in insulin sensitivity and pancreatic 
β-cell function in animal models of diabetes mellitus [11-13]. 
Phlorizin has proved useful as a physiological research tool and has been used in this 
capacity for more than 150 years. But there are several limitation of this SGLT inhibitor 
is that it is non-selective SGLT inhibitor, inhibiting SGLT2 and SGLT1 inhibitor. 
[14,15,] 
Another limitation of phlorizin embrace the poor oral bioavailability and susceptibility of 
O-linkage to be cleave by the β-glucosidase in the gastrointestinal tract. [16,17]. For this 
reason phlorizin has to be given by parentral route in order to be effective. In order to 
improve the shortcomings of the phlorizin, another compounds or derivatives of phlorizin 
came into existences which are discussed later in the article. 
 
2. T-1095: 
It is improved derivative of phlorizin that can be administered orally as prodrug. [18]. T-
1095 is another O-glucoside with greater metabolic firmness as compared to the 
phlorizin. Though it is a non-selective SGLT inhibitor. [16, 18, 19]. It was discontinued 
in the Phase-II clinical trial. [16]. 
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3. Sergiflozin Etabonate: 
Sergliflozin is highly specific inhibitor of SGLT2 in its glycated form [20, 21]. 
Sergliflozin is found to be very potent and and selective for rat SGLT2 with a selectivity 
ration of 41. Based on Ki value (Table No.2) the selectivity of sergliflozin towards 
human SGLT2 was also found to be far above the ground. Sergliflozin etabonate (Active 
form of Sergliflozin) encouraged excretion of glucose depending on blood glucose level. 
Upon chronic administration of sergliflozin etabonate to Zuker fatty rats there is no 
alteration in body weight ( 622.6 ± 12.4, 614.7 ± 23.2, and 615.8 ± 15.6g for vehicle, 
10mg/kg and 30 mg/kg group respectively) as well as the food intake (30.6 ± 2.0, 29.5 ± 
2.5, and 32.1 ± 1.3g for vehicle 10mg/kg and 30 mg/kg group respectively) but it reduces 
both the glycated heamoglobin (Figure No.3A, 3B) and fasting plasma glucose (Figure 
No.4) [22] 
Sergliflozin was discontinued for various unfavorable effects such as non-desired 
pharmaceutical properties, non-selectivity and development of new SGLT2 inhibitors. 
[23-25] 
Table No.2: Ki values of sergliflozin etabonate, sergliflozin, and phlorizin for rat 
SGLTs 
 Ki Value (nM) 
Rat SGLT1 Rat SGLT2 
Sergliflozin etabonate 3350 ± 110 651 ± 149 
Sergliflozin 704 ± 254 17.1 ± 2.6 
Phlorizin 275 ± 153 41.8 ± 11.4 
Data are presented as means±S.E.M. from 3 experiments. An AMG uptake experiment was performed with 
COS-7 cells transiently transfected with rat SGLT1 or SGLT2, and the Ki values for each SGLT were 
calculated. (Copyright 2009, Elsevier, Data adapted with permission from Fujimori et al, (Yoshikazu 
Fujimori, Kenji Katsuno, Kazuma Ojima, Ikumi Nakashima, Shigeru Nakano, Yukiko Ishikawa-Takemura, 
Hiroshi Kusama, Masayuki Isaji, Sergliflozin etabonate, a selective SGLT2 inhibitor, improves glycemic 
control in streptozotocin-induced diabetic rats and Zucker fatty rats, European Journal of Pharmacology, 
Volume 609, Issues 1–3, 1 May 2009, Pages 148-154) 
N
at
ur
e 
Pr
ec
ed
in
gs
 : 
do
i:1
0.
10
38
/n
pr
e.
20
12
.7
05
7.
1 
: P
os
te
d 
31
 M
ar
 2
01
2
 Figure No. 3: Acute effects of sergliflozin etabonate in Zucker fatty rats. Sergliflozin etabonate was orally 
administered to fed Zucker fatty rats. Blood glucose concentrations (A) were measured, and the AUC0–6 h 
for blood glucose (B) was calculated. Data are presented as means±S.E.M. (n=7–8). *Pb0.05, **Pb0.01 vs. 
vehicle group. (Adapted with permission from Fujimori et al, Yoshikazu Fujimori, Kenji Katsuno, Kazuma Ojima, 
Ikumi Nakashima, Shigeru Nakano, Yukiko Ishikawa-Takemura, Hiroshi Kusama, Masayuki Isaji, Sergliflozin 
etabonate, a selective SGLT2 inhibitor, improves glycemic control in streptozotocin-induced diabetic rats and 
Zucker fatty rats, European Journal of Pharmacology, Volume 609, Issues 1–3, 1 May 2009, Pages 148-154 
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Figure No. 4: Chronic effects of sergliflozin etabonate in Zucker fatty rats. Sergliflozin etabonate was orally 
administered to Zucker fatty rats twice daily for 2 weeks. At the end of the administration period, glycated 
hemoglobin (A) was determined; and the oral glucose tolerance test (2 g/kg) was performed. Plasma glucose 
concentrations (B) were measured, and the AUC0–4 h for plasma glucose (C) was calculated from the plasma 
glucose concentration during the oral glucose tolerance test. Data are presented as means±S.E.M. (n=4–5). *Pb0.05, 
**Pb0.01 vs. vehicle group. (Adapted with permission from Fujimori et al, Yoshikazu Fujimori, Kenji Katsuno, 
Kazuma Ojima, Ikumi Nakashima, Shigeru Nakano, Yukiko Ishikawa-Takemura, Hiroshi Kusama, Masayuki Isaji, 
Sergliflozin etabonate, a selective SGLT2 inhibitor, improves glycemic control in streptozotocin-induced diabetic 
rats and Zucker fatty rats, European Journal of Pharmacology, Volume 609, Issues 1–3, 1 May 2009, Pages 148-
154) 
 
 
4. Dapagliflozin: 
Dapagliflizon is potent inhibitor of human SGLT2 and has EC50 of 1.1 nM with 1200 fold 
selectivity for human SGLT2 over SGLT1 and contain C-glucoside in lieu of O-glycoside 
linkage which makes it β-glucosidase resistant.[26] It is under clinical trial. Earlier 
clinical trials showed the efficacy of dapagliflozin versus placebo in the patients of type 2 
diabetes mellitus and metformin [27]  and sulfonylurea glimepiride [28]. 
A randomized noninferiority clinical trial conducted by Nauck etal [29] of dapagliflozin 
versus gliplizide. The trial showed that dapagliflozin reduces the plasma glucose level in 
the same manner as of glipizide with lesser episodes of hypoglycemia. It also reduces the 
systolic as well as diastolic blood pressure in the type 2 diabetes mellitus patients. 
Consequently the patients treated with dapagliflozin experiences the weight loss while 
patients receiving the glipizide sustained weight gain. 
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Dapagliflozin has marked effect on blood glucose level. Some excellent investigations [3-
33], in the treatment naïve patients for 12 weeks, in patients on metformin monotherapy 
for 24 weeks and in poorly controlled patients receiving insulin and oral antidiabetic drug 
for 12 weeks shows that dapagliflozin has dose dependent effect on the PPG (Post 
prandial glucose) levels in poorly controlled patients while dose dependency is lesser in 
case of treatment-naïve patients. The above study clarifies that higher filtered load of 
glucose in poorly controlled patients in responsible for higher excretion of glucose from 
the kidney which results in the better HbA1c values. [34] (Table No 2).
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Table No.2: Effect of dapagliflozin on blood glucose parameters 
 
 
 
AUC, area under the curve; FPG, fasting plasma glucose; HbA1c, hemoglobin A1c; OAD, oral antidiabetic drug; PPG, postprandial plasma glucose. a Mean change in AUC 
((mg/dL)*min). bPlasma glucose levels measured after 120 min during a 75 g oral glucose tolerance test. 
(Adapted with permission from List et al (List JF, Whaley JM. Glucose dynamics and mechanistic implications of SGLT2 inhibitors in animals and humans. Kidney Int 2011; 79 
(Suppl 120): S20–S27.)
 
 
 
 
Blood glucose 
Measure 
 
 
 
Dapagliflozin monotherapy 
in 389 treatment-naïve patients 
in a 12-week study 
 
 
Dapagliflozin as an add-on to metformin 
in 546 patients inadequately controlled by 
metformin alone in a 24-week study 
 
 
 
Dapagliflozin combination 
therapy in 71 patients 
inadequately 
controlled by insulin plus 
OADs in a 12-week study 
 2.5mg 5mg 10mg 20mg 50mg Placebo 2.5 mg 5mg 10mg Placebo 10mg 20mg Placebo 
Mean change 
from baseline 
in FPG 
(mg/dl) 
 
-16 
 
-19 
 
-21 
 
-24 
 
-31 
 
-6 
 
-17.8 
 
-21.5 
 
-23.5 
 
-6.0 
 
-2.4 
 
-9.6 
 
17.8 
Change from 
baseline in 
PPG 
-
9382a 
-
8478a 
-
10149a 
-
7053a 
-
10,093a 
 
-3182a 
     
-34.3b 
 
-41.9b 
 
18.7b 
Mean 
absolute 
change from 
baseline in 
HbA1c (%) 
 
-0.71 
 
-0.72 
 
-0.85 
 
-0.55 
 
-0.90 
 
-0.18 
 
-0.67 
 
-0.70 
 
-0.84 
 
-0.30 
 
-0.61 
 
-0.69 
 
0.09 
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5. Remigliflozin: 
Remigliflozin is an O-glycoside SGLT2 inhibitor. It was developed as a consequential 
candidate for SGLT2 inhibition with better selectivity and pharmacokinetic profile.[35]. 
Its selectivity towards human SGLT2 was higher as compared to human SGLT1. (Ki 
values: 12.4 and 4520 nmol/l towards human SGLT2 and human SGLT1 respectively). 
While remigliflozin etabonate inhibit SGLT2 more potently in vivo as compared to the 
Phlorizin ,Sergliflozin and T-1095. Remigliflozin is an O-glycoside which is susceptible 
to β-glucosidase.[36]. Moreover, it causes reduction of blood glucose and body weight as 
well as the blood pressure in type2 diabetes mellitus patients. [23]. 
 
6. Canagliflozin: 
Canagliflozin is another C-glucoside and has ~200-fold selectivity for SGLT2 (IC50 2.2 
nM) as compared to SGLT1 (IC50 0.44µM) (Table No. 3) [37]. One recent research has 
shown the potency and selectivity of Canagliflozin towards SGLT2 inhibition. There was 
noteworthy diminution in the blood glucose level receiving the Canagliflozin at 3mg/kg 
without any alteration in the food intake in hyperglycemic high-fat diet fed KK (HG-KK) 
mice (Figure No.5). On the contrary there is only slight reduction in the blood glucose 
levels in normoglycemic mice (Figure). Consequently, it can be said that there will be 
less hypoglycemic episodes with Canagliflozin. Furthermore, Canagliflozin remarkably 
increases the urinary glucose excretion [38] (Table). At this moment in time 
Canagliflozin is under Phase-III clinical trial. 
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 IC50 (nM)  
Compound hSGLT1 hSGLT2 GLUT1 UGEa 
(mg/day) 
Canagliflozin 910 2.2 >10000 3696 
 
Table No. 3: hSGLT1, hSGLT2, Facilitated Glucose Transporter 1 (GLUT1) Inhibitory Activity, and 
Rat Urinary Glucose Excretion (UGE) Data for Canagliflozin. (. (Adapted with permission from 
Sumihiro Nomura et al , (Discovery of Canagliflozin, a Novel C-Glucoside with Thiophene Ring, as 
Sodium-Dependent Glucose Cotransporter 2 Inhibitor for the Treatment of Type 2 Diabetes Mellitus 
Sumihiro Nomura, Shigeki Sakamaki, Mitsuya Hongu, Eiji Kawanishi, Yuichi Koga, Toshiaki Sakamoto, 
Yasuo Yamamoto, Kiichiro Ueta, Hirotaka Kimata, Keiko Nakayama, and Minoru Tsuda-Tsukimoto 
Journal of Medicinal Chemistry 2010 53 (17), 6355-6360, Copyright 2010 @American Chemical Society) 
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 Figure No.5. Effects of single oral dosing of Canagliflozin on blood glucose levels and food intake in 
high-fat diet fed KK (HF-KK) (A) and normal (B) mice. Data are expressed as the mean ( SEM (n = 
5): * P < 0.05, ** P < 0.01 vs vehicle. (Adapted with permission from Sumihiro Nomura et al , (Discovery 
of Canagliflozin, a Novel C-Glucoside with Thiophene Ring, as Sodium-Dependent Glucose Cotransporter 
2 Inhibitor for the Treatment of Type 2 Diabetes Mellitus Sumihiro Nomura, Shigeki Sakamaki, Mitsuya 
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Hongu, Eiji Kawanishi, Yuichi Koga, Toshiaki Sakamoto, Yasuo Yamamoto, Kiichiro Ueta, Hirotaka 
Kimata, Keiko Nakayama, and Minoru Tsuda-Tsukimoto Journal of Medicinal Chemistry 2010 53 (17), 
6355-6360, Copyright 2010 @American Chemical Society) 
 
Table No. 4: Clinical progress of some important SGLT2 inhibitors for the 
treatment of type 2 diabetes mellitus 
Compound Manufacturing Company Development Phase 
T-1095 Tanabe Discontinued 
TS-033 Taisho Discontinued 
AVE2268 Sanofi-Aventis Discontinued 
YM-543 Astellas/Kotobuki Discontinued 
Remogliflozin GlaxoSmithKline Discontinued 
Sergliflozin GlaxoSmithKline/Kiss
ei 
Discontinued 
Dapagliflozin Bristol-Myers 
Squibb/AstraZeneca 
Phase III 
Canagliflozin JNJ/Mitsubishi Tanabe Phase III 
BI 10773 Boehringer Ingelheim Phase II 
BI 44847 Boehringer 
Ingelheim/Ajinomoto 
Phase II 
R-7201 Roche/Chugai Phase II 
TS-071  Taisho Phase II 
LX4211  Lexicon Phase II 
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Reproduced with permission from Masayuki Isaji Masayuki Isaji, SGLT2 inhibitors: molecular design and 
potential differences in effect, Kidney International (2011) 79 (Suppl 120), S14–S19) Copyright 2011,@ 
International Society of Nephrology. 
 
Contemporary view and prospective advantages of the SGLT2 inhibitors: 
Many new SGLT2 inhibitors have been developed as result of modification in the 
prototype Phlorizin. After withdrawal of non-selective SGLT2 inhibitors viz. Phlorizin, 
T-1095 etc, newer SGLT2-selective inhibitors such as sergliflozin, remogliflozin, AVE—
2268 and YM-543 have also been taken off. Though new selective SGLT2 inhibitors 
curtail the adverse effects resulted from SGLT1 inhibition such as gastrointestinal 
disturbances which is associated with the non-selective SGLT2 inhibitors. 
Sergliflozin and Dapagliflozin reduces the blood pressure probably by their osmotic 
diuretic and tuboglomerular reflex. As far as the Pharmacokinetic profile is concerned C-
glycosides are longer acting as compared to O-glycosides. Consequently, C-glycosides 
suppress the postprandial hyperglycemia and fasting hyperglycemia more prominently 
than short acting O-glycosides. Controlling the postprandial hyperglycemia is vital for 
thwarting cardiovascular adverse effects.[39].  
The important gain from SGLT2 inhibitors is the co-transportation of the sodium as well 
as glucose which reduces the reabsorption of both the glucose and sodium which results 
in diuretic action of SGLT2 inhibitors. Another benefit of SGLT2 inhibitor is the 
reduction of blood glucose without any change in the body weight which is the adverse 
effect associated with most of the Oral Antidiabetic drugs (OADs) such as sulfonylureas, 
insulin and thiazolidinediones (TZDs). 
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Limitations of the SGLT2 inhibitors: 
Although the mechanism of action of SGLT2 inhibitors may resides potential benefits in 
it, nevertheless they are associated with an assortment of precincts as well such as 
polyuria and polydipsia which results in hypovolemia particularly in the dehydrated 
patients. Urinary excretion of glucose also results in an increased risk of urinary tract 
infections (UTIs) and genitourinary infections. Furthermore, most of the Oral 
Antidiabetic Drugs (OADs) either improve insulin resistance or insulin secretion whereas 
SGLT2 inhibitors are thought to increase the glycemic control through urinary excretion 
of the same, irrespective of how the glucose level increased. Consequently diminution of 
glucotoxicity might improve the insulin resistance as well as the insulin secretion. 
 
Conclusion:  
Currently overabundances of therapies are available to target the diabetes mellitus. 
Nevertheless, targeting the glucose level remain on top priority in sizeable percentage of 
type 2 diabetes mellitus patients. Increased blood glucose level contributes to the 
succession and development of type 2 diabetes mellitus. Reducing the blood glucose 
level through increased urinary excretion of sugar put forward impending advantages of 
better glycemic control, minimum risk of hypoglycemia and sympathetic effect on the 
body weight. At present many companies are developing potential SGLT2 inhibitors with 
different selectivity, pharmacokinetic profiles, potency and efficacy. SGLT2 inhibitors 
are expected to improve the glycemic control, insulin resistance as well as the 
conservation of pancreatic β-cells. The insulin independent mechanism of action of 
SGLT2 inhibitors might provide better treatment for the type 2 diabetes mellitus patients. 
These are expected to provide better synergistic results when used as combinatorial 
therapy with other antidiabetic drugs despite predictable adverse effects for instance 
polyuria, urinogenital infections, and UTIs. 
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Figure No.1 , Reabsorption of glucose from the renal proximal tubules by the sodium glucose cotransporters 
SGLT2 . Almost all of the glucose entering glomeruli in the afferent glomerular arterioles is filtered into the nephron 
fluid of the proximal renal tubules. Most (up to 90%) of this filtered glucose is reabsorbed in the initial proximal 
convoluted segment (S1) by SGLT2 located at the luminal surface of proximal tubular cells. Remaining glucose is 
reabsorbed from the filtrate in themore distal convoluted and straight segments by SGLT1. Glucose within the 
proximal tubular cells is then transported back to the interstitial compartment and thence to the plasma by the 
facilitative glucose transporters GLUT2 in the S1 segment, respectively. In normal individuals with an average 
plasma glucose concentration of 5–5.5 mmol/L (90–100mg/dL), approximately 160–180 g of glucose is filtered 
daily, with less than 0.5 g/day of glucose appearing in the urine. Based on Bakris et al. and Bays 
 
 
 
 
Figure No. 2. Normal glucose homeostasis. This outlines the hormonal interactions that are important in regulating 
normal glucose homeostasis. Normal fasting glucose homeostasis involves the hormonal regulation of glucose 
utilization and production, as well as the filtration and reabsorption of glucose by the kidney10. Under basa 
conditions, glucose uptake by the tissues is matched by glucose production from the liver; this enables fine 
regulation of glucose at a fixed level. Gluconeogenesis in the liver helps prevent hypoglycaemia. (Reproduced with 
permission from Edward C. Chao, Copyright @2010, Macmilan Publishers Limited.) 
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